Cyberkinetics Appoints Daniel E. Geffken to Board of Directors.FOXBOROUGH, Mass. -- Cyberkinetics Neurotechnology Systems, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CYKN) (Cyberkinetics) announced today the appointment of Daniel E. Geffken to its Board of Directors. Mr. Geffken, who brings to the Board more than 20 years of corporate finance, business development and investor relations Investor relations The process by which the corporation communicates with its investors. experience, will also serve on the Company's audit committee. Mr. Geffken is currently Senior Vice President and Chief Financial Officer of OmniSonics Medical Technologies, Inc. and has previously worked in several early-stage, high-growth life science companies, including Transkaryotic Therapies, Inc. and CytoTherapeutics Inc. He is a past chairman of the Association of Bioscience Financial Officers and the finance committee of the Massachusetts Biotechnology Council. He holds a B.S. from The Wharton School at the University of Pennsylvania (body, education) University of Pennsylvania - The home of ENIAC and Machiavelli. http://upenn.edu/. Address: Philadelphia, PA, USA. and a M.B.A. from Harvard Business School Harvard Business School, officially named the Harvard Business School: George F. Baker Foundation, and also known as HBS, is one of the graduate schools of Harvard University. . "We are delighted to welcome Dan to Cyberkinetics' Board of Directors," said Tim Surgenor, Chief Executive Officer of Cyberkinetics. "His experience in financing growing healthcare companies will be invaluable to Cyberkinetics, particularly when we seek additional capital investment and evaluate strategic expansion." Commenting on his appointment to Cyberkinetics' Board, Mr. Geffken stated, "Cyberkinetics has established an important leadership position in neurotechnology through its pioneering BrainGate program. The Company has made tremendous progress during the BrainGate pilot clinical trial which has opened the door to multiple opportunities. I look forward to helping the Cyberkinetics team achieve its goals." About Cyberkinetics Neurotechnology Systems, Inc. Cyberkinetics, a leader in neurotechnology, an emerging field driven by advances in neuroscience, computer science, and engineering, is focused on treating diseases and disorders of the nervous system. Cyberkinetics' first product, BrainGate(TM) Neural Interface System, is designed to give severely paralyzed par·a·lyze tr.v. par·a·lyzed, par·a·lyz·ing, par·a·lyz·es 1. To affect with paralysis; cause to be paralytic. 2. To make unable to move or act: paralyzed by fear. individuals a long-term, direct brain-computer interface for the purpose of communication and control of a computer and other devices. Patients are currently being enrolled into a pilot clinical trial to test its safety and effectiveness. Cyberkinetics' intellectual property features key technologies licensed from Brown University, the Massachusetts Institute of Technology Massachusetts Institute of Technology, at Cambridge; coeducational; chartered 1861, opened 1865 in Boston, moved 1916. It has long been recognized as an outstanding technological institute and its Sloan School of Management has notable programs in business, , Emory University, and the University of Utah The University of Utah (also The U or the U of U or the UU), located in Salt Lake City, is the flagship public research university in the state of Utah, and one of 10 institutions that make up the Utah System of Higher Education. . Cyberkinetics is headquartered in Foxborough, Massachusetts and conducts engineering and research in Salt Lake City, Utah For ships of the United States Navy of the same name, see . Salt Lake City is the capital and the most populous city of the U.S. state of Utah. The name of the city is often shortened to Salt Lake, or its initials, S.L.C. . More information is available at www.cyberkineticsinc.com. Forward Looking Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement: This press release contains forward-looking statements. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see our filings with the Securities and Exchange Commission. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion